Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of -18.84% and -80.46%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?